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A B S T R A C T
Gabapentin (GAB) is a newer second-line antiepileptic drug (AED) used in children. This is a multi-centre
retrospective observational study of the efﬁcacy, tolerability and retention rate in 105 children, aged 0–
17.5 years (mean 10.1) over a 14 year period.
Themedian age of epilepsy onsetwas 2.5 years (range 0–14.6). 72% started GAB as at least the 3rd AED,
with 43% having been withdrawn from at least 2 AEDs. 77% had focal and 52% symptomatic epilepsies.
The maintenance doses for GAB ranged 6.0–87.3 mg/kg/day (mean 43.7). The study comprised 157
person-treatment years for GAB.
GAB was well tolerated with 55% remaining on treatment beyond 1 year. No serious adverse events
were reported whilst on GAB, but 39% reported possibly and probably related adverse events. Seizure
improvement (<50% seizure frequency compared to baseline) at more than 12months of treatment, was
reported in 35% of patients starting GAB, including 6% who remained seizure free.
The results demonstrated the efﬁcacy and tolerability of GAB in children with difﬁcult to treat
epilepsies, and a good response to treatment beyond 12months, in both focal and generalised epilepsies.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
About 30% of children and young people with epilepsies do not
respond to the ﬁrst two appropriate antiepileptic drugs (AEDs), and
can be considered to have ‘‘intractable’’ or ‘‘difﬁcult to treat’’
epilepsies.1,2 Gabapentin (GAB) is an AED with proven efﬁcacy in
treating partial seizures and secondarily generalised seizures.3 It
binds intracellularly to the a2d1-subunit and a2d2-subunit of
neuronal voltage-dependant calcium channels, impairing their
normal trafﬁcking function, leading to reduced neurotransmitter
release.4 GAB ﬁrst had marketing authorisation in the USA as an
AED in 1994, and in the UK has marketing authorisation for use in
children over 6 years of age with difﬁcult to treat epilepsies.
However, there are few studies of GAB in children.5
There are few studies published on its long-term use,
tolerability, toxicity, efﬁcacy, and retention. A few clinical trials
have been published, but these have had relatively short follow-up
periods of 12–24 weeks.6,7 We proposed to undertake this
retrospective chart review, of all children starting GAB treatment* Corresponding author at: University of Nottingham, Academic Division of Child
Health, E Floor East Block, Queen’s Medical Centre, Nottingham NG7 2UH, UK.
Tel.: +44 0 115 924 9924; fax: +44 0 970 9228.
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doi:10.1016/j.seizure.2011.08.013for epilepsies at 3 adjacent paediatric neurology/epilepsy centres
in the UK, with outcomes observed beyond 12 months.
This study reports on the use of GAB in 105 separate treatment
episodes in 105 paediatric patientswith difﬁcult to treat epilepsies,
at 3 centres over a 14 year period.
2. Methods
Children under 18 years of age starting treatment with GAB
from February 1995 to August 2009 were ascertained retrospec-
tively from hospital pharmacy and paediatric neurology databases
in three tertiary referral paediatric neurology departments. GAB
was prescribed as adjunctive therapy for controlling difﬁcult to
treat focal or generalised epilepsies by the Consultant paediatric
neurologists at the tertiary departments. A retrospective chart
review using a standard proforma to capture demographic data,
aetiology, epilepsy syndrome, seizure frequency, medication
dosage, concomitant AEDs, efﬁcacy and adverse events was
recorded at more than 2, 6 and 12 months from starting that
AED. The proforma was used at all sites to ensure recording
consistency. Epilepsies were classiﬁed using all available clinical
data, by the International League Against Epilepsies’ (ILAE) 1988
system.8 Datawas analysed using SPSS 18.0 on an intention to treat
basis. As this was not a prospective trial with allocation of
treatments, but an observational study of recent local practice, thevier Ltd. All rights reserved.
Table 1
Aetiology and classiﬁcation of epilepsies treated.
Aetiology and
classiﬁcation
Number of treatment
episodes (%)
IFE 4 (3.8)
IGE 2 (1.9)
SFE 46 (44)
SGE 7 (6.6)
SUE 2 (1.9)
CFE 12 (11.4)
CGE 7 (6.6)
CUE 1 (0.9)
UFE 18 (17.1)
UGE 1 (0.9)
UUE 5 (4.7)
IFE, Idiopathic Focal Epilepsy; IGE, Idiopathic Generalised Epilepsy; SFE, Symptom-
atic Focal Epilepsy; SGE, Symptomatic Generalised Epilepsy; SUE, Sympatomatic
Unclassiﬁed Epilepsy; CFE, Cryptogenic Focal Epilepsy; CGE, Cryptogenic General-
ised Epilepsy; CUE, Cryptogenic Unclassiﬁed Epilepsy; UFE, Unknown Focal
Epilepsy; UGE, Unknown Generalised Epilepsy; UUE, Unknown Unclassiﬁed
Epilepsy.
Table 3
Number of concomitant AEDs.
Number of concomitant
AEDs
Number of treatment
episodes (%)
0 14 (13)
1 52 (51)
2 28 (27)
3 8 (8)
4 1 (1)
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complete data set including all patients who had started the
AED, including those in whom it had been withdrawn. A few
patients were omitted from the perceived efﬁcacy analyses at
some time windows if they had not been withdrawn but were not
observed during that time window.
Statistical methods included simple descriptive statistics, Chi-
squared for differences in aetiology and seizure type, and Kaplan–
Meier survival plot for time on the AED.
This was an observational non-intervention study. The protocol
has been tried and tested,9 andwas registered as a clinical audit by
the Nottingham University Hospital’s NHS Trust, Shefﬁeld
Children’s NHS Foundation Trust, and Birmingham Children’s
Hospital NHS Foundation Trust.
3. Results
105 treatment episodes in 105 children (55% male) were
ascertained. Patients starting GAB ranged from 1.3 to 17.5 years
(normal distribution, mean 10.1), including 17 under 6 years of
age. The population had mostly early onset of seizures, with a
median age of onset of 2.5 years (range 0 months to 14.7 years).
GAB was used in epilepsies with a variety of aetiologies and
classiﬁcations, most commonly in symptomatic focal epilepsies in
46 (44%). In all, 81 (77%) of cases had focal, and 55 (52%)
symptomatic epilepsies (Table 1).
Brain magnetic resonance imaging (MRI) and electroencepha-
lography (EEG) reports were available in 91% and 99% of cases
respectively. MRI was abnormal in 53/96 (55%) and EEG wasTable 2
Number of AEDs previously withdrawn.
Number of AEDs
withdrawn
Number of treatment
episodes (%)
0 39 (38)
1 20 (19)
2 16 (15)
3 11 (10)
4 8 (8)
5 3 (3)
7 2 (2)
8 2 (2)
9 1 (1)
14 1 (1)
15 1 (1)abnormal in 66/104 (63%), with 37/104 (36%) having at least one
EEG demonstrating focal epileptiform discharges.
The intractable nature of this study population’s epilepsies is
demonstrated by the number of previously withdrawn (Table 2)
and concomitant AEDs (Table 3). Only 4 patients had received GAB
as the 1st choice, 25 patients as the 2nd choice, with 76 patients
received GAB as 3rd or later choices. 1 patient had beenwithdrawn
from 15 AEDs prior to starting GAB, and 1 patient was on 4 other
AEDs in addition to GAB.
This study comprised 157 young person-treatment years for
GAB.Meanmaximumdosagewas 43.7 mg/kg/day (range 6.0–87.3,
median 44.2).
16 patients on GAB achieved monotherapy. Of these patients, 1
had Idiopathic Generalised Epilepsy, 8 had Symptomatic Focal
Epilepsies, 1 had a Symptomatic Generalised Epilepsy, 2 had
Cryptogenic Focal Epilepsies and 4 had Unknown Focal Epilepsies.
Of these 16, 10 had a signiﬁcant improvement (greater than 50%
seizure reduction compared to pre-GAB baseline) and 1 was
seizure free. For 4 of these patients, GAB was the 1st choice, 4 the
2nd choice, 2 the 3rd choice, 4 the 4th choice, and 2 the 5th choice
of AED.
Possibly and probably related adverse events were reported in
39% of GAB treatment episodes. The most frequently reported
adverse events being behavioural problems (such as disruption at
school and mood swings) in 16 (15%), sleep problems in 9 (8.5%),
and weight/appetite changes in 6 (6%). 64 (61%) reported no
adverse events attributed to GAB treatment (Table 4).Most adverse
events appeared within the ﬁrst 3 months of treatment. The
adverse events seen were often at the lower-end of the
recommended dosage ranges. Most adverse events were mild,
and resolved without requiring withdrawal of medication,
although GAB was withdrawn from 14 (13%) because of adverse
reactions (either alone or with additional lack of efﬁcacy). No
serious events were recognised in any of the treatment episodes.
No patients died during their period of study observation.
57 (54%) children withdrew from GAB: 10 because of adverse
events, 4 due to lack of efﬁcacy and adverse effects, 40 due to
perceived lack of efﬁcacy, 2 due to being seizure free, and 1 due to
disliking the taste and poor compliance.
Data was available for analysis from 66 treatment episodes at
2 < 6 months, 59 at 6 < 12 months and 58 at over 12 months
follow up. 47 children were not followed up beyond 12 months,
due to missing data as a result of not attending clinic frequently
enough, missing appointments, transfer to adult services, or
withdrawal from GAB prior to 12 months.
The retention rate beyond 12 months, of all patients com-
menced on treatment and assuming those lost to follow up had
come off the AED, were 55% (58/105) beyond one year follow up
since commencing treatment (Fig. 1).
Seizure response rates of greater than 50% reduction were
reported at 12 months or longer follow-up, with 35% (37/105) of
those starting treatment experiencing a beneﬁt, remaining either
seizure free (6/105), or experiencing some seizures but with a
greater than 50% reduction in seizure frequency (31/105)
compared to baseline. At 2 < 6 months follow-up, of those
observed 41% (27/66) experienced an improvement, and at
Table 4
Reported adverse events on Gabapentin (%).
None Behavioural problems Sleeping problems Weight/appetite change Co-ordination problems Othera
64 (61) 16 (15) 9 (9) 6 (6) 4 (4) 6 (6)
a Other included rash, vomiting, hair loss, increased seizures, parotid gland swelling, low mood.
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enced an improvement compared to baseline. Patients achieving
an initially good response tended to maintain a reduction in
seizure frequency.
4. Discussion
Gabapentin in this retrospective pragmatic observational study
has been shown to be effective andwell tolerated for long term use
as an AED in children with intractable epilepsies, as was suggested
by previous short term controlled trials in children with secondary
generalised and refractory partial seizures.6,7,10 Gabapentin was
equally effective against partial seizures in children with and
without intellectual disability.11
This study adds to the existing literature by demonstrating the
effects of GAB in a deﬁned paediatric cohort, evaluating the effects
of GAB on seizure frequency and its tolerability and safety. It shows
that the ﬁndings of short term controlled trials stand up to the test
of time and longer follow-up in ‘‘real’’, unselected, patients
managed as part of every-day practice, i.e. who are not in a
controlled trial. This is important as GAB has a reputation of being
relatively ineffective: a view fostered by the modest dose
recommendation given in the original Summary of Product
Characteristics, which was up to about half the doses used
commonly now, and the preferential marketing of Pregabalin,
which has the same mechanism of action,12 by the main
manufacturer of GAB. It is of interest to note that 3 multi-centre,
randomised, double-blind, placebo-controlled trials on patients
with refractory partial epilepsy have demonstrated efﬁcacy of
Pregabalin as an adjunctive antiepileptic therapy, with 31–51% of
patients showing a 50% reduction in seizure frequency,13
compared to 35% in this observational study.
Whilst 39% on GAB reported some adverse effects, there were
no serious adverse effects in 157 young person-years of exposure.
Behavioural problems such as tantrums, deﬁance and aggression
have also been associated with GAB treatment for epilepsies and
[(Fig._1)TD$FIG]
Fig. 1. Discontinuation of Gabapentin over 365 days.other neurological conditions, and typically resolve on dose
modiﬁcation or withdrawal.14–16 15% of children started on GAB
experienced behavioural problems, such as mood swings, negative
thoughts and disruption at school. However, some were tolerated
by the caregivers and treatment was only withdrawn because of
adverse events in 13%. Some children had behavioural and learning
difﬁculties before GAB, so it is difﬁcult to attribute these all to the
medication per se, although those with pre-existing problems are
more susceptible to exacerbation.17 Whatever the multi-factorial
causes, it is nonetheless important to recognise that deterioration
in cognitive function, mood and behavioural adverse effects may
well be encountered after starting GAB.
The main limitation of this study is the retrospective nature
of the data collection, so it is possible that some adverse events
may have been due to concomitant AEDs or othermedications, and
that some adverse reactions were not recorded in the medical
records.
The main strength of this study is the ‘‘reality’’ of drug use, in
the practical clinical setting where a variety of confounding factors
can inﬂuence treatment as opposed to the strict control of variables
in the randomised control trial setting. Assessing the impact on
patient behaviour, mood and cognition would require a prospec-
tive study that records objectively changes in behaviour, mood and
cognition before attributing change in behaviour and cognition to
use of GAB.
Retention was favourable for GAB, with 55% remaining on
treatment beyond 12 months since commencing treatment. The
results of those continuing treatment throughout the three
observation periods of 2 < 6, 6 < 12 and 12+ months since
commencing treatment are the most useful measure of how
GAB performed in terms of efﬁcacy and tolerability in the
paediatric cohort. The results of this study support the ﬁndings
of tolerability and efﬁcacy of similar studies of children with
intractable epilepsies on GAB.10
Seizure freedomwas achieved in 6% started on GAB, 3 of whom
had focal epilepsy of unknown aetiology, 1 with symptomatic focal
epilepsy, 1 with cryptogenic focal epilepsy and one patient with
idiopathic generalised epilepsy. A further 29% started on GAB had a
signiﬁcant reduction (<50% fewer seizures compared to baseline)
in seizure frequency beyond 12 months follow up. As this was
retrospective, seizure frequency was not always recorded from a
diary, but as with normal clinical practice, some indication of
seizure frequency and change in frequency as perceived by the
caregivers and the prescribing paediatric neurologist was usually
recorded even when diary counts were not, e.g. a change from
‘‘several seizures a day’’ to ‘‘several a week’’ comprised a greater
than 50% seizure reduction.When no convincing seizure frequency
estimate was available for a visit of a child on GAB, they were
excluded from the perceived efﬁcacy analysis. Due to the
conservative nature of what was considered an improvement,
these results demonstrated that a substantial number of young
patients with epilepsies will beneﬁt from treatment with GAB,
even with generalised epilepsies.
Themethods used in this study are comparable to those used in
other studies of newer AEDs including Levetiracetam, Zonisamide,
Topiramate, Lamotrigine and Clobazam9,18,19 so the results may be
compared to the performance of those drugs in the paediatric
population.
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dailydoses.20OtherAEDshavea simpler onceor twicedaily regimen
and may come in dispersible or syrup formulation. GAB has a bitter
taste and many children ﬁnd swallowing tablets and capsules
difﬁcult.21 One patient found the taste particularly unpalatable and
discontinued as a consequence, however all other patients tolerated
the taste if they could swallow the capsule. Physicians may be
avoiding GAB due to its formulation in favour of medicines with a
more favourable formulation, especially in younger children.
Our study conﬁrms the efﬁcacy, tolerability and safety proﬁle of
GAB in a paediatric cohort with intractable epilepsies. The
multicentre nature of this study improves the generalisability of
the data to paediatric cohorts with intractable epilepsies. Multi-
centre prospective studies would be required to demonstrate the
longer-term efﬁcacy and the impact GAB will have on behaviour,
mood and cognitive function of children.
5. Conclusions
This study conﬁrms the efﬁcacy and safety proﬁle of GAB in
young people with intractable epilepsies.
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